Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Generoath Co. Ltd. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions span 3 distinct examiners and 3 distinct art units, indicating separate examination assignments across the portfolio.
MOORE, JOHN DAVID is the busiest examiner, with 1 pending matter. Each pending matter should be evaluated in its own examiner and art-unit context rather than treated as a single prosecution stream.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, JOHN DAVID | 1 | 61.1% | +28.3% |
| SHIN, DANA H | 1 | 26.9% | +26.9% |
| BARRERA, IMMACULADA | 1 | 30.0% | +80.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246578 | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF | SHIN, DANA H | 56d |
| 18858540 | Methods of Treating Retinal Degenerative Diseases Using AIMP2-DX2 and Optionally a Target Sequence for miR-142 and Compositions Thereof | MOORE, JOHN DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245248 | Method for Preparing Stem Cells Having Improved Engraftment Capability | BARRERA, IMMACULADA | 28d |
| 18246578 | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF | SHIN, DANA H | 56d |
| 18858540 | Methods of Treating Retinal Degenerative Diseases Using AIMP2-DX2 and Optionally a Target Sequence for miR-142 and Compositions Thereof | MOORE, JOHN DAVID | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1635 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858540 | Methods of Treating Retinal Degenerative Diseases Using AIMP2-DX2 and Optionally a Target Sequence for miR-142 and Compositions Thereof | MOORE, JOHN DAVID | 1638 | §102§103 | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18246578 | METHODS OF TREATING AGE-RELATED MACULAR DISEASES USING AIMP2-DX2 AND OPTIONALLY A TARGET SEQUENCE FOR miR-142 AND COMPOSITIONS THEREOF | SHIN, DANA H | 1635 | §112Other | Non-Final OA | 56d | Pending | Mar 24, 2023 |
| 18245248 | Method for Preparing Stem Cells Having Improved Engraftment Capability | BARRERA, IMMACULADA | 1671 | §103 | Final Rejection | 28d | Pending | Mar 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGeneroath Co. Ltd. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
John David Moore has the most, with 1 of Generoath Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
